Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-03 00:10 | 2025-12-31 | COCP | Cocrystal Pharma, Inc. | FROST PHILLIP MD ET AL | Director, 10% owner | BUY | $0.95 | 50,000 | $47,275 | 1,838,551 |
| 2026-01-03 00:04 | 2025-12-30 | FBRX | Forte Biosciences, Inc. | Riley Antony A | Officer | BUY | $26.33 | 9,680 | $254,833 | 41,520 |
| 2026-01-03 05:30 | 2025-12-30 | CRMD | CorMedix Inc. | DUNTON ALAN W | Director | OPT+S | $13.00 | 20,000 | $260,000 | 40,250 |
| 2026-01-03 00:05 | 2025-12-31 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Director, Officer | BUY | $1.03 | 5,000 | $5,150 | 291,421 |
| 2026-01-03 03:02 | 2025-12-31 | AXSM | Axsome Therapeutics, Inc. | Saad Mark E | Director | OPT+S | $165.18 | 37,577 | $6,206,969 | 10,002 |
| 2026-01-03 01:13 | 2025-12-30 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | SELL | $0.64 | 27 | $17 | 0 |
| 2026-01-03 01:32 | 2025-12-30 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.62 | 78,377 | $48,429 | 2,472,297 |
| 2026-01-03 00:30 | 2026-01-02 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $485.43 | 8,300 | $4,029,076 | 36,781 |
| 2026-01-03 01:20 | 2025-12-30 | PTCT | PTC THERAPEUTICS, INC. | Klein Matthew B. | Director, Officer | SELL | $76.64 | 8,089 | $619,941 | 341,875 |
| 2026-01-03 02:01 | 2026-01-02 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $62.62 | 1,798 | $112,585 | 50,440 |
| 2025-12-31 20:10 | 2025-12-29 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $5.98 | 12,234 | $73,124 | 783,590 |
| 2026-01-01 05:00 | 2025-12-29 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Director, Officer | OPT+S | $21.72 | 1,330,868 | $28,902,460 | 20,267,429 |
| 2026-01-01 01:45 | 2025-12-29 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $41.97 | 66,304 | $2,782,905 | 443,739 |
| 2026-01-01 00:10 | 2025-12-30 | COCP | Cocrystal Pharma, Inc. | FROST PHILLIP MD ET AL | Director, 10% owner | BUY | $0.97 | 20,000 | $19,310 | 1,788,551 |
| 2026-01-01 00:05 | 2025-12-29 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | Officer | SELL | $6.97 | 9,933 | $69,233 | 0 |
| 2026-01-01 00:33 | 2025-12-29 | IRD | Opus Genetics, Inc. | Gallagher Cam | Director | BUY | $1.97 | 164,000 | $323,687 | 83,000 |
| 2025-12-31 00:00 | 2025-12-29 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,085.04 | 3,593 | $3,898,531 | 92,190,516 |
| 2025-12-31 00:12 | 2025-12-29 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | Officer | OPT+S | $12.06 | 3,611 | $43,558 | 0 |
| 2025-12-31 00:10 | 2025-12-23 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Officer | SELL | $12.23 | 4,170 | $51,009 | 164,392 |
| 2025-12-31 05:03 | 2025-12-23 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $6.28 | 11,671 | $73,345 | 795,824 |
| 2025-12-31 00:15 | 2025-12-30 | MBIO | MUSTANG BIO, INC. | Jin David | Director | BUY | $0.96 | 247 | $238 | 286 |
| 2025-12-31 00:16 | 2025-12-30 | MBIO | MUSTANG BIO, INC. | Chill Adam J. | Director | SELL | $0.95 | 4 | $4 | 375 |
| 2025-12-31 00:01 | 2025-12-26 | COGT | Cogent Biosciences, Inc. | Kearns Evan | Officer | SELL | $38.70 | 65,000 | $2,515,500 | 109,398 |
| 2025-12-31 00:01 | 2025-12-26 | COGT | Cogent Biosciences, Inc. | Green John L. | Officer | SELL | $38.68 | 77,000 | $2,978,360 | 131,834 |
| 2025-12-31 00:01 | 2025-12-26 | COGT | Cogent Biosciences, Inc. | Sachs Jessica | Officer | SELL | $38.70 | 82,642 | $3,198,245 | 133,938 |
| 2025-12-31 00:01 | 2025-12-26 | COGT | Cogent Biosciences, Inc. | Robinson John Edward | Officer | SELL | $38.74 | 90,000 | $3,486,600 | 140,002 |
| 2025-12-31 00:01 | 2025-12-26 | HYPD | HYPERION DEFI, INC. | Strahlman Ellen R | Director | BUY | $3.66 | 30,880 | $113,092 | 34,869 |
| 2025-12-30 21:49 | 2025-12-29 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | Officer | SELL | $34.38 | 85 | $2,922 | 50,450 |
| 2025-12-31 01:46 | 2025-12-26 | ARWR | Arrowhead Pharmaceuticals Inc. | Ferrari Mauro | Director | SELL | $70.00 | 7,530 | $527,100 | 69,053 |
| 2025-12-31 01:41 | 2025-12-26 | MRUS | Merus N.V. | GENMAB A/S | 10% owner | BUY | $97.00 | 76,922,983 | $7,461,529,351 | 0 |
| 2025-12-31 01:46 | 2025-12-29 | ARWR | Arrowhead Pharmaceuticals Inc. | Anzalone Christopher Richard | Director, Officer | OPT+S | $69.13 | 51,726 | $3,575,575 | 3,805,926 |
| 2025-12-31 00:17 | 2025-12-30 | MBIO | MUSTANG BIO, INC. | Herskowitz Neil | Director | SELL | $0.96 | 247 | $238 | 145 |
| 2025-12-31 01:54 | 2025-12-23 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director | SELL | $2.07 | 1,851 | $3,825 | 0 |
| 2025-12-31 02:47 | 2025-12-30 | IMNM | Immunome Inc. | SIEGALL CLAY B | Director, Officer | BUY | $21.15 | 4,729 | $100,018 | 665,254 |
| 2025-12-31 00:31 | 2025-12-29 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $502.79 | 22,500 | $11,312,710 | 0 |
| 2025-12-31 00:34 | 2025-12-29 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $62.44 | 1,809 | $112,954 | 51,353 |
| 2025-12-30 00:05 | 2025-12-24 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,085.17 | 2,629 | $2,852,920 | 92,194,109 |
| 2025-12-30 00:00 | 2025-12-23 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,085.04 | 240 | $260,409 | 92,196,738 |
| 2025-12-30 01:14 | 2025-12-23 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | Officer | OPT+S | $35.84 | 145,000 | $5,196,742 | 15,000 |
| 2025-12-30 00:30 | 2025-12-29 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | Director, Officer | SELL | $5.31 | 25,000 | $132,740 | 1,164,818 |
| 2025-12-30 00:58 | 2025-12-26 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $39.32 | 20,000 | $786,380 | 100,000 |
| 2025-12-30 05:55 | 2025-12-22 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Director | SELL | $28.53 | 2,881 | $82,195 | 741,259 |
| 2025-12-29 20:15 | 2025-12-26 | MNPR | Monopar Therapeutics | Vu Quan Anh | Officer | BUY | $69.95 | 1,500 | $104,925 | 1,500 |
| 2025-12-30 05:00 | 2025-12-23 | ROIV | Roivant Sciences Ltd. | Pulik Richard | Officer | OPT+S | $22.43 | 406,731 | $9,122,326 | 239,413 |
| 2025-12-30 05:00 | 2025-12-23 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $22.47 | 275,000 | $6,179,745 | 1,654,597 |
| 2025-12-30 00:05 | 2025-12-22 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $41.49 | 2,905 | $120,533 | 377,435 |
| 2025-12-30 02:42 | 2025-12-22 | EOLS | Evolus, Inc. | MOATAZEDI DAVID | Director, Officer | SELL | $7.15 | 10,539 | $75,361 | 354,388 |
| 2025-12-30 03:31 | 2025-12-23 | BNTC | Benitec Biopharma Inc. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director, 10% owner | BUY | $13.20 | 144,223 | $1,903,138 | 1,848,156 |
| 2025-12-29 20:24 | 2025-12-24 | VSTM | Verastem, Inc. | Calkins Daniel | Officer | SELL | $7.86 | 80 | $629 | 109,758 |
| 2025-12-30 05:01 | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Officer | OPT+S | $42.00 | 15,000 | $630,005 | 88,787 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.